| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 05/23/2001 | EP1100522A1 Pulmonary delivery of active agents |
| 05/23/2001 | EP1100509A1 Use of biogenic estrogen sulfamates for hormone replacement therapy |
| 05/23/2001 | EP1100492A1 INDOLE sPLA 2? INHIBITORS |
| 05/23/2001 | EP1100483A2 Glucocorticoid-selective anti-inflammatory agents |
| 05/23/2001 | EP1100478A1 Estradiol-containing patch for transdermal administration of hormones |
| 05/22/2001 | US6236946 Nuclear receptor ligands and ligand binding domains |
| 05/22/2001 | US6235714 Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses |
| 05/17/2001 | WO2001034800A1 19 human secreted proteins |
| 05/17/2001 | WO2001034767A2 22 human secreted proteins |
| 05/17/2001 | WO2001034643A1 24 human secreted proteins |
| 05/17/2001 | WO2001034623A1 29 human secreted proteins |
| 05/17/2001 | WO2001034593A1 Compound with growth hormone releasing properties |
| 05/17/2001 | WO2001034562A1 Aralkyl-1,2-diamines having calcimimetic activity and preparation mode |
| 05/17/2001 | WO2001034181A2 Methods of treating short stature disorders related to the short stature homeobox-containing (shox) gene |
| 05/17/2001 | WO2001034166A1 Transplant/implant device and method for its production |
| 05/17/2001 | WO2001034126A2 Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt) |
| 05/17/2001 | WO2001034117A1 A method for chemoprevention of prostate cancer |
| 05/17/2001 | WO2001009116A3 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)- 2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE |
| 05/17/2001 | WO2001007471A9 Cell cycle and proliferation proteins |
| 05/17/2001 | WO2001005390A3 Method for treating chronic pain using mek inhibitors |
| 05/17/2001 | WO2000040613A9 Insulin-like growth factor (igf) i mutant variants |
| 05/17/2001 | WO2000024755A9 Ovary-specific genes and proteins |
| 05/17/2001 | CA2390880A1 Aralkyl-1,2-diamines having calcimimetic activity and preparation mode |
| 05/17/2001 | CA2390834A1 Transplant/implant device and method for its production |
| 05/17/2001 | CA2390632A1 Methods of treating short stature disorders related to the short stature homeobox-containing (shox) gene |
| 05/17/2001 | CA2390438A1 19 human secreted proteins |
| 05/17/2001 | CA2390421A1 24 human secreted proteins |
| 05/17/2001 | CA2388008A1 29 human secreted proteins |
| 05/17/2001 | CA2387964A1 22 human secreted proteins |
| 05/16/2001 | EP1099706A2 Estrane sulphamate derivatives as steroid sulphatase inhibitors |
| 05/16/2001 | EP1099443A1 Transplant/implant device and method for its production |
| 05/16/2001 | EP1098975A1 Orphan cytokine receptor |
| 05/16/2001 | EP1098874A1 Benzocycloheptenes, method for the production thereof, pharmaceutical preparations containing these compounds, and their use for producing medicaments |
| 05/16/2001 | EP1098636A1 A wet granulation method for preparing a stable pharmaceutical formulation |
| 05/16/2001 | CN1294913A Pharmaceutical use of compound |
| 05/16/2001 | CN1294911A Substituted nitrobenzene derivative for medicine and other use |
| 05/16/2001 | CN1065765C Chinese medicine for curing female endocrinopathy |
| 05/16/2001 | CN1065758C Application of tea pigments in preparation of medicine for goiter |
| 05/15/2001 | US6232330 Therapeutically effective amount of an insulin sensitivity enhancer(pioglitazone,troglitazone and salts) in combination with an aldose reductase inhibitor(tolurestat,epalrestat,imirestat,zenarestat) |
| 05/15/2001 | US6232310 Antidiabetic agents |
| 05/15/2001 | US6232307 2-phenyl-1-(4-(2-aminoethoxy)-benzyl)-indole compounds useful as estrogenic agents |
| 05/10/2001 | WO2001032878A2 A novel polypeptide hormone phosphatonin |
| 05/10/2001 | WO2001032687A1 10 human secreted proteins |
| 05/10/2001 | WO2001032680A2 18-nor-steroids as selectively active estrogens |
| 05/10/2001 | WO2001032677A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 05/10/2001 | WO2001032675A1 32 human secreted proteins |
| 05/10/2001 | WO2001032659A1 Isoquinoline and quinazoline derivatives for the treatment of cns disorders |
| 05/10/2001 | WO2001032648A1 Novel cyclopropanes as cgrp antagonists, medicaments containing said compounds and method for the production thereof |
| 05/10/2001 | WO2001032614A2 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 05/10/2001 | WO2001032596A1 Phenoxy carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | WO2001032212A1 Drugs, drinks or foods |
| 05/10/2001 | WO2001032144A1 Dry powder compositions having improved dispersivity |
| 05/10/2001 | WO2001032130A2 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | WO2001000652A3 11β LONG-CHAIN SUBSTITUTED ESTRATRIENES, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11β LONG-CHAIN SUBSTITUTED ESTRATRIENES, AND THEIR USE FOR PRODUCING MEDICAMENTS |
| 05/10/2001 | WO2000047720A3 Pancreatic progenitor cells, methods and uses related thereto |
| 05/10/2001 | WO2000034334A9 DNA ENCODING A MAMMALIAN RECEPTOR (fb41a) AND USES THEREOF |
| 05/10/2001 | US20010001097 Stress-follower circuit configuration |
| 05/10/2001 | CA2390025A1 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | CA2389644A1 A novel polypeptide hormone phosphatonin |
| 05/10/2001 | CA2389415A1 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 05/10/2001 | CA2387801A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 05/10/2001 | CA2387754A1 10 human secreted proteins |
| 05/10/2001 | CA2386641A1 32 human secreted proteins |
| 05/09/2001 | EP1097945A2 Monoclonal and chimeric antibody specific for human tumor necrosis factor |
| 05/09/2001 | EP1097942A2 Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes |
| 05/09/2001 | EP1097719A1 NEP inhibitors for the treatment of female sexual dysfunction |
| 05/09/2001 | EP1097718A1 NPY antagonists for the treatment of female sexual dysfunction |
| 05/09/2001 | EP1097707A1 Treatment of female sexual dysfunction |
| 05/09/2001 | EP1097706A1 Phosphodiesterase inhibitors for the treatment of female sexual dysfunction |
| 05/09/2001 | CN1294015A Medicine for treating thyroid enlargement and thyroidism |
| 05/09/2001 | CN1294014A Medicine for treating mastoplasia |
| 05/08/2001 | US6229029 11β-aryl substituted 14,17-ethanoestratriens, method for the production of these compounds and their use in the production of medicaments |
| 05/08/2001 | CA2324484A1 Compounds for the treatment of female sexual dysfunction |
| 05/08/2001 | CA2323464A1 Compounds for the treatment of female sexual dysfunction |
| 05/08/2001 | CA2323191A1 Compounds for the treatment of female sexual dysfunction |
| 05/08/2001 | CA2323183A1 Compounds for the treatment of female sexual dysfunction |
| 05/03/2001 | WO2001031045A1 Mammalian-type glycosylation in plants |
| 05/03/2001 | WO2001031021A1 Multiple sclerosis-related superantigen |
| 05/03/2001 | WO2001030844A1 Dna encoding human alpha1g-c t-type calcium channel |
| 05/03/2001 | WO2001030764A1 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof |
| 05/03/2001 | WO2001030763A1 Process for producing optically active naphthalene derivative and optical resolver therefor |
| 05/03/2001 | WO2001030762A1 Imidazol-4-ylmethanols use as inhibitors of steroid c17-20 lyase |
| 05/03/2001 | WO2001030358A1 Contraceptive medicament based on a progesterone and an oestrogen and method for producing the same |
| 05/03/2001 | WO2001030357A1 Hormonal composition based on a progesterone and an oestrogen and use thereof |
| 05/03/2001 | WO2001030356A1 Hormonal composition based on a progestational agent and an oestrogen and use thereof |
| 05/03/2001 | WO2001030355A1 Contraceptive medicine based on a progestational agent and an oestrogen and preparation method |
| 05/03/2001 | WO2001030351A1 Oral formulations for anti-tumor compounds |
| 05/03/2001 | WO2001030300A2 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 05/03/2001 | DE19952147A1 Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung New cyclopropanes, pharmaceutical compositions containing them and methods for their preparation |
| 05/03/2001 | DE19949179A1 Nukleinsäuresequenzen von Hyperplasien und Tumoren der Schilddrüse Nucleic acid sequences of hyperplasias and tumors of the thyroid |
| 05/03/2001 | CA2389217A1 Mammalian-type glycosylation in plants |
| 05/03/2001 | CA2389031A1 Dna encoding human alpha1g-c t-type calcium channel |
| 05/03/2001 | CA2388508A1 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof |
| 05/03/2001 | CA2388483A1 Process for producing optically active naphthalene derivative and optical resolver therefor |
| 05/03/2001 | CA2388338A1 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 05/03/2001 | CA2387869A1 Imidazol-4-ylmethanols use as inhibitors of steroid c17-20 lyase |
| 05/03/2001 | CA2387648A1 Oral formulations for anti-tumor compounds |
| 05/03/2001 | CA2387229A1 Biodegradable microparticles with novel erythropoietin stimulating protein |
| 05/02/2001 | EP1095038A1 Antagonists of gonadotropin releasing hormone |
| 05/02/2001 | EP1094810A1 Use of prenyltransferase inhibitors for preparing a medicine for treating pathologies resulting from heterotrimeric g protein membrane fixation |